SCHEMBL5859178

SCHEMBL5859178

COC1=C(OC)C(=O)C(Cc2ccc(C(=O)Nc3ccc(C(F)(F)F)cc3)c(-c3cccnc3)c2)=C(C)C1=O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 1/20 0.45
XBP1 P17861 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HIF1A Q16665 2/20 0.43
EPAS1 Q99814 2/20 0.43
ABL1 P00519 4/20 0.42
BCR P11274 1/20 0.42
LRRK2 Q5S007 2/20 0.42
SRPK3 Q9UPE1 1/20 0.42
NAMPT P43490 1/20 0.42
EPHX2 P34913 2/20 0.41
NR3C1 P04150 1/20 0.41
KDR P35968 1/20 0.41
TRPV1 Q8NER1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5859917 0.93 MAPT (0.48) MAPTMEN1KMT2ALMNAXBP1
SCHEMBL5862249 0.91 MTTP (0.45) MAPTSMN1; SMN2
SCHEMBL5859125 0.90 PSMD14 (0.49) MAPTKMT2ALMNASMN1; SMN2ABL1
SCHEMBL5860289 0.86 PPARA (0.43) MAPTLMNASMN1; SMN2NPSR1ABL1
SCHEMBL6094574 0.84 LRRK2 (0.56) HIF1AEPAS1LRRK2SRPK3NAMPT
SCHEMBL5860012 0.84 PPARA (0.46) SMN1; SMN2
SCHEMBL5860138 0.83 PSMD14 (0.49) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL5859037 0.83 MAPT (0.49) MAPTMEN1KMT2ALMNAXBP1
SCHEMBL6095885 0.82 TMPRSS4 (0.50) MEN1KMT2ASMN1; SMN2KDR
SCHEMBL5859170 0.81 TBXAS1 (0.45) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7122543-B2 Substituted benzoic acid derivatives having NF-κB inhibiting action DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2006-10-17 US disclosed
EP-1437339-A1 SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-KAPPA B INHIBITING ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-07-14 EP disclosed
US-20040039061-A1 Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039061-A1 Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity NFKBIA, NFKB2, IKBKB MAPT 4242/4885MEN1 4230/4885KMT2A 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.